We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Infrainguinal Bypass and Amputation on a Par for Patient Survival

By HospiMedica International staff writers
Posted on 29 Jun 2010
A new study comparing the results of infrainguinal bypass (IB) and major amputation (AMP) in limb ischemia patients with severe systemic comorbidities found no difference between the two in the overall number of major adverse events or postoperative length of stay. More...


Researchers at Brigham and Women's Hospital (Boston, MA, USA) reviewed procedural codes from the 2005-2008 U.S. National Surgical Quality Improvement Program database, using propensity score matching to identify all patients undergoing either IB or AMP. A total of 780 IB patients and 792 AMP patients were identified, with no significant differences among the demographic, preoperative, or anesthetic variables. Patients with systemic or local infections were excluded.

The researchers found that there was no difference in the overall number of major adverse events or postoperative length of stay between the AMP and IB groups. When using risk-adjusted propensity-matched comparison, the researchers found that the IB group had a lower 30-day postoperative mortality than the AMP group (6.5% versus 10%, respectively). Also, IB was associated with significantly higher rates of return to the operating room (27.6% versus 14.1%), as well as a trend toward higher bleeding requiring transfusion (2.1% versus 0.9%). Major amputation, however, had higher rates of pulmonary embolism (0.9% versus 0%) and urinary tract infection (5.2% versus 2.7%). The study was presented at the 64th Vascular Annual Meeting of the Society for Vascular Surgery (SVS), held during June 2010 in Boston (MA, USA).

"Our study shows that the decision to perform infrainguinal bypass or major amputation should depend on well-established predictors of graft patency and functional success rather than presumptions about the perioperative risks associated with the two treatments,” said lead author and study presenter said Neal R. Barshes, M.D., M.P.H, of the division of vascular and endovascular surgery.

High-risk patients with multiple comorbidities are defined as class 4 or 5 by the American Society of Anesthesiologists (ASA); or ASA class 3 with either congestive heart failure (CHF) within 30 days, myocardial infarction (MI) within 6 months, renal failure (serum creatinine higher than 3 mg/dL or dialysis-dependence), dyspnea at rest, or ventilator dependence.

Related Links:

Brigham and Women's Hospital




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.